{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:02:16Z","timestamp":1792425736017,"version":"4.5.0"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:00:00Z","timestamp":1581638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.00212","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T00:33:25Z","timestamp":1581640405000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":254,"title":["Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics"],"prefix":"10.3389","volume":"11","author":[{"given":"Konstantinos","family":"Lazaridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates J.","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/35097557","article-title":"Induction, assembly, maturation and maintenance of a postsynaptic apparatus","volume":"2","author":"Sanes","year":"2001","journal-title":"Nat Rev Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.conb.2005.12.003","article-title":"Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost","volume":"16","author":"Kummer","year":"2006","journal-title":"Curr Opin Neurobiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers."},{"key":"B7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A systematic review of population based epidemiological studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1084\/jem.144.3.739","article-title":"Pathological mechanisms in experimental autoimmune myasthenia gravis. II Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies","volume":"144","author":"Lindstrom","year":"1976","journal-title":"J Exp Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long-term effects of repeated plasma exchange in myasthenia gravis","volume":"1","author":"Newsom-Davis","year":"1979","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e108327","DOI":"10.1371\/journal.pone.0108327","article-title":"Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients","volume":"9","author":"Kordas","year":"2014","journal-title":"PLoS ONE."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1111\/j.1742-4658.2007.05935.x","article-title":"Muscle and neuronal nicotinic acetylcholine receptors","volume":"274","author":"Kalamida","year":"2007","journal-title":"Structure, function and pathogenicity FEBS J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jaut.2013.12.008","article-title":"Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor","volume":"52","author":"Vrolix","year":"2014","journal-title":"J Autoimmun."},{"key":"B13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(95)92652-6","article-title":"Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen","volume":"346","author":"Vincent","year":"1995","journal-title":"Lancet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jneuroim.2007.07.018","article-title":"Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: a combination of immunoadsorbents results in increased efficiency","volume":"190","author":"Kostelidou","year":"2007","journal-title":"J Neuroimmunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jneuroim.2008.06.020","article-title":"Towards antigen-specific apheresis of pathogenic autoantibodies as a further step in the treatment of myasthenia gravis by plasmapheresis","volume":"202","author":"Zisimopoulou","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1073\/pnas.77.2.755","article-title":"Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits","volume":"77","author":"Tzartos","year":"1980","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"163","author":"Tzartos","year":"1998","journal-title":"Immunol Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s12031-009-9271-y","article-title":"Antigenic structure of the human muscle nicotinic acetylcholine receptor main immunogenic region","volume":"40","author":"Luo","year":"2010","journal-title":"J Mol Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0165-5728(81)90015-1","article-title":"Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis","volume":"1","author":"Lefvert","year":"1981","journal-title":"J Neuroimmunol."},{"key":"B20","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin Exp Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B25","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"J Neurol Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3233\/JND-180313","article-title":"Serum acetylcholine receptor antibodies before the clinical onset of myasthenia gravis","volume":"5","author":"Strijbos","year":"2018","journal-title":"J Neuromuscul Dis."},{"key":"B27","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0896-8411(91)90017-7","article-title":"Anti-acetylcholine receptor antibodies in neonatal myasthenia gravis: heterogeneity and pathogenic significance","volume":"4","author":"Eymard","year":"1991","journal-title":"J Autoimmun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/0090-1229(77)90027-7","article-title":"An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis","volume":"7","author":"Lindstrom","year":"1977","journal-title":"Clin Immunol Immunopathol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1073\/pnas.70.12.3334","article-title":"Studies on purified eel acetylcholine receptor and anti-acetylcholine receptor antibody","volume":"70","author":"Patrick","year":"1973","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1212\/WNL.47.6.1552","article-title":"A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis","volume":"47","author":"Beeson","year":"1996","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","article-title":"A systematic review of diagnostic studies in myasthenia gravis","volume":"16","author":"Benatar","year":"2006","journal-title":"Neuromuscul Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/ene.13300","article-title":"Multiple antibody detection in 'seronegative' myasthenia gravis patients","volume":"24","author":"Hong","year":"2017","journal-title":"Eur J Neurol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cccn.2005.05.035","article-title":"A sensitive non-isotopic assay for acetylcholine receptor autoantibodies","volume":"364","author":"Hewer","year":"2006","journal-title":"Clin Chim Acta."},{"key":"B35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.cca.2015.07.030","article-title":"An update on laboratory diagnosis in myasthenia gravis","volume":"449","author":"Oger","year":"2015","journal-title":"Clin Chim Acta."},{"key":"B36","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1002\/mus.20854","article-title":"Frequency of seronegativity in adult-acquired generalized myasthenia gravis","volume":"36","author":"Chan","year":"2007","journal-title":"Muscle Nerve."},{"key":"B38","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jns.2010.10.023","article-title":"Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China","volume":"301","author":"Yang","year":"2011","journal-title":"J Neurol Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.nmd.2010.12.003","article-title":"Recombinant expression of the AChR-alpha1 subunit for the detection of conformation-dependent epitopes in Myasthenia Gravis","volume":"21","author":"Ching","year":"2011","journal-title":"Neuromuscul Disord."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain."},{"key":"B41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/archneurol.2012.437","article-title":"Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis","volume":"69","author":"Jacob","year":"2012","journal-title":"Arch Neurol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/ene.12270","article-title":"Antibodies to clustered acetylcholine receptor: expanding the phenotype","volume":"21","author":"Devic","year":"2014","journal-title":"Eur J Neurol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","article-title":"Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis","volume":"72","author":"Rodriguez Cruz","year":"2015","journal-title":"JAMA Neurol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","article-title":"MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2013A multinational study","volume":"284","author":"Tsonis","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/nyas.13592","article-title":"Serological and experimental studies in different forms of myasthenia gravis","volume":"1413","author":"Vincent","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s12264-012-1256-0","article-title":"Clinical significance of detection of antibodies to fetal and adult acetylcholine receptors in myasthenia gravis","volume":"28","author":"Shi","year":"2012","journal-title":"Neurosci Bull."},{"key":"B47","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","article-title":"Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population","volume":"343","author":"Chang","year":"2014","journal-title":"J Neurol Sci"},{"key":"B48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pediatrneurol.2019.01.016","article-title":"Cell-based versus enzyme-linked immunosorbent assay for the detection of acetylcholine receptor antibodies in chinese juvenile myasthenia gravis","volume":"98","author":"Yan","year":"2019","journal-title":"Pediatr Neurol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1172\/JCI119048","article-title":"Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function","volume":"98","author":"Riemersma","year":"1996","journal-title":"J Clin Invest."},{"key":"B50","doi-asserted-by":"publisher","first-page":"14426","DOI":"10.1038\/s41598-017-14350-8","article-title":"Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient","volume":"7","author":"Saxena","year":"2017","journal-title":"Sci Rep."},{"key":"B51","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jim.2018.06.016","article-title":"Immunostick ELISA for rapid and easy diagnosis of myasthenia gravis","volume":"460","author":"Trakas","year":"2018","journal-title":"J Immunol Methods."},{"key":"B52","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/labmed\/lmy038","article-title":"A simple, rapid and non-radiolabeled immune assay to detect anti-AChR antibodies in myasthenia gravis","volume":"50","author":"Bokoliya","year":"2019","journal-title":"Lab Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jneuroim.2014.09.013","article-title":"Expression of extracellular domains of muscle specific kinase (MuSK) and use as immunoadsorbents for the development of an antigen-specific therapy","volume":"276","author":"Skriapa","year":"2014","journal-title":"J Neuroimmunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/01.LAB.0000028144.48023.9B","article-title":"Anti-p110 autoantibodies identify a subtype of \u201cseronegative\u201d myasthenia gravis with prominent oculobulbar involvement","volume":"82","author":"Scuderi","year":"2002","journal-title":"Lab Invest."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology."},{"key":"B57","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1136\/jnnp.2006.102517","article-title":"Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in The Netherlands","volume":"78","author":"Niks","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"B58","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1111\/j.1468-1331.2008.02176.x","article-title":"MuSK-positive myasthenia gravis is rare in the Polish population","volume":"15","author":"Kostera-Pruszczyk","year":"2008","journal-title":"Eur J Neurol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1468-1331.2009.02624.x","article-title":"Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece","volume":"16","author":"Tsiamalos","year":"2009","journal-title":"Eur J Neurol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jneuroim.2010.10.023","article-title":"Clinical and immunological differences between early and late-onset myasthenia gravis in Japan","volume":"230","author":"Suzuki","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1212\/01.WNL.0000129274.12702.92","article-title":"MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG","volume":"62","author":"Ohta","year":"2004","journal-title":"Neurology."},{"key":"B62","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/mus.23847","article-title":"Pure ocular anti-musk myasthenia under no immunosuppressive treatment","volume":"48","author":"Zouvelou","year":"2013","journal-title":"Muscle Nerve."},{"key":"B63","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity."},{"key":"B64","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"J Autoimmun."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology."},{"key":"B66","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B67","doi-asserted-by":"publisher","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1\u20133 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS ONE."},{"key":"B68","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies\u2013a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clin Chim Acta."},{"key":"B71","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jneuroim.2011.09.007","article-title":"Development of a highly sensitive diagnostic assay for muscle-specific tyrosine kinase (MuSK) autoantibodies in myasthenia gravis","volume":"241","author":"Trakas","year":"2011","journal-title":"J Neuroimmunol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"577076","DOI":"10.1016\/j.jneuroim.2019.577076","article-title":"A novel MuSK cell-based myasthenia gravis diagnostic assay","volume":"337","author":"Han","year":"2019","journal-title":"J Neuroimmunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1111\/ene.13979","article-title":"Clinical analysis of Chinese anti-low-density-lipoprotein-receptor-associated protein 4 antibodies in patients with myasthenia gravis","volume":"26","author":"Li","year":"2019","journal-title":"Eur J Neurol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell."},{"key":"B75","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","article-title":"Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis","volume":"123","author":"Shen","year":"2013","journal-title":"J Clin Invest."},{"key":"B79","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/mus.25591","article-title":"Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis","volume":"56","author":"Li","year":"2017","journal-title":"Muscle Nerve."},{"key":"B80","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J Autoimmun."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s00415-017-8514-z","article-title":"Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis","volume":"264","author":"Cordts","year":"2017","journal-title":"J Neurol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Ann Clin Transl Neurol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/mus.25438","article-title":"Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle Nerve."},{"key":"B84","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1084\/jem.164.4.1043","article-title":"Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin","volume":"164","author":"Williams","year":"1986","journal-title":"J Exp Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1212\/WNL.37.8.1329","article-title":"Antifilamin, antivinculin, and antitropomyosin antibodies in myasthenia gravis","volume":"37","author":"Yamamoto","year":"1987","journal-title":"Neurology."},{"key":"B86","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2249.1990.tb05440.x","article-title":"Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin","volume":"82","author":"Aarli","year":"1990","journal-title":"Clin Exp Immunol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1161\/hh2301.100981","article-title":"The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system","volume":"89","author":"Bang","year":"2001","journal-title":"Circ Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1212\/WNL.43.8.1581","article-title":"Titin antibodies in myasthenia gravis: identification of a major immunogenic region of titin","volume":"43","author":"Gautel","year":"1993","journal-title":"Neurology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1212\/WNL.57.9.1579","article-title":"Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?","volume":"57","author":"Buckley","year":"2001","journal-title":"Neurology."},{"key":"B90","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1001\/archneur.58.6.885","article-title":"Anti-titin antibodies in myasthenia gravis: tight association with thymoma and heterogeneity of nonthymoma patients","volume":"58","author":"Yamamoto","year":"2001","journal-title":"Arch Neurol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1001\/archneur.62.3.442","article-title":"Striational antibodies in myasthenia gravis: reactivity and possible clinical significance","volume":"62","author":"Romi","year":"2005","journal-title":"Arch Neurol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1196\/annals.1405.040","article-title":"Myasthenia gravis in the elderly: is it different?","volume":"1132","author":"Aarli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early- and late-onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurol Scand."},{"key":"B94","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1111\/j.1749-6632.1998.tb10978.x","article-title":"Anti-titin and antiryanodine receptor antibodies in myasthenia gravis patients with thymoma","volume":"841","author":"Baggi","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s004150050604","article-title":"Muscle autoantibodies in subgroups of myasthenia gravis patients","volume":"247","author":"Romi","year":"2000","journal-title":"J Neurol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1007\/s00415-004-0479-z","article-title":"The significance of titin antibodies in myasthenia gravis\u2013correlation with thymoma and severity of myasthenia gravis","volume":"251","author":"Chen","year":"2004","journal-title":"J Neurol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/mus.23882","article-title":"Do acetylcholine receptor and striated muscle antibodies predict the presence of thymoma in patients with myasthenia gravis?","volume":"49","author":"Choi Decroos","year":"2014","journal-title":"Muscle Nerve."},{"key":"B98","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1212\/WNL.59.1.92","article-title":"The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970\u20131999","volume":"59","author":"Somnier","year":"2002","journal-title":"Neurology."},{"key":"B99","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.jneuroim.2016.01.018","article-title":"Titin antibodies in \u201cseronegative\u201d myasthenia gravis\u2013A new role for an old antigen","volume":"292","author":"Stergiou","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1038\/s41598-019-41730-z","article-title":"Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and\/or myocarditis","volume":"9","author":"Kufukihara","year":"2019","journal-title":"Sci Rep."},{"key":"B101","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1002\/mus.10294","article-title":"Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro","volume":"27","author":"Skeie","year":"2003","journal-title":"Muscle Nerve."},{"key":"B102","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1002\/ana.410320419","article-title":"Ryanodine receptor autoantibodies in myasthenia gravis patients with a thymoma","volume":"32","author":"Mygland","year":"1992","journal-title":"Ann Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1212\/01.WNL.0000125254.99397.68","article-title":"Anti-ryanodine receptor antibodies and FK506 in myasthenia gravis","volume":"62","author":"Takamori","year":"2004","journal-title":"Neurology."},{"key":"B104","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/(sici)1097-4598(199803)21:3<329::aid-mus6>3.0.co;2-c","article-title":"Myasthenia gravis sera containing antiryanodine receptor antibodies inhibit binding of [3H]-ryanodine to sarcoplasmic reticulum","volume":"21","author":"Skeie","year":"1998","journal-title":"Muscle Nerve."},{"key":"B105","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1111\/j.1468-1331.2007.01785.x","article-title":"Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features","volume":"14","author":"Romi","year":"2007","journal-title":"Eur J Neurol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","article-title":"The search for new antigenic targets in myasthenia gravis","volume":"1275","author":"Cossins","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology."},{"key":"B108","doi-asserted-by":"publisher","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","article-title":"Autoantibodies to agrin in myasthenia gravis patients","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS ONE."},{"key":"B109","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuroscience.2018.01.015","article-title":"Induction of anti-agrin antibodies causes myasthenia gravis in mice","volume":"373","author":"Yan","year":"2018","journal-title":"Neuroscience."},{"key":"B110","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","article-title":"Novel autoantibodies to a voltage-gated potassium channel Kv1.4 in a severe form of myasthenia gravis","volume":"170","author":"Suzuki","year":"2005","journal-title":"J Neuroimmunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/archneurol.2009.229","article-title":"Autoimmune targets of heart and skeletal muscles in myasthenia gravis","volume":"66","author":"Suzuki","year":"2009","journal-title":"Arch Neurol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ene.12234","article-title":"Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies","volume":"21","author":"Suzuki","year":"2014","journal-title":"Eur J Neurol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"J Neurol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/377232a0","article-title":"Failure of postsynaptic specialization to develop at neuromuscular junctions of rapsyn-deficient mice","volume":"377","author":"Gautam","year":"1995","journal-title":"Nature."},{"key":"B115","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1749-6632.1998.tb10972.x","article-title":"Rapsyn antibodies in myasthenia gravis","volume":"841","author":"Agius","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B116","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/j.1749-6632.1998.tb10974.x","article-title":"Antirapsyn antibodies occur commonly in patients with lupus","volume":"841","author":"Agius","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B117","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1001\/jamaneurol.2016.2032","article-title":"Clinical characteristics of patients with double-seronegative myasthenia gravis and antibodies to cortactin","volume":"73","author":"Cortes-Vicente","year":"2016","journal-title":"JAMA Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/nyas.13502","article-title":"Diagnostic utility of cortactin antibodies in myasthenia gravis","volume":"1412","author":"Illa","year":"2018","journal-title":"Ann N Y Acad Sci."},{"key":"B120","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.autrev.2014.08.038","article-title":"Identification of a novel myositis-associated antibody directed against cortactin","volume":"13","author":"Labrador-Horrillo","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B121","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1365-2249.1995.tb03674.x","article-title":"Antibodies to acetylcholinesterase cross-reacting with thyroglobulin in myasthenia gravis and Graves's disease","volume":"100","author":"Mappouras","year":"1995","journal-title":"Clin Exp Immunol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/08916930400021360","article-title":"The prevalence of anti-acetylcholinesterase antibodies in autoimmune disease","volume":"37","author":"Geen","year":"2004","journal-title":"Autoimmunity."},{"key":"B123","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.11.004","article-title":"Anti-acetylcholinesterase antibodies associate with ocular myasthenia gravis","volume":"218","author":"Provenzano","year":"2010","journal-title":"J Neuroimmunol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1083\/jcb.200307164","article-title":"MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction","volume":"165","author":"Cartaud","year":"2004","journal-title":"J Cell Biol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2013a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Zoltowska Katarzyna","year":"2015","journal-title":"J Neurol Sci."},{"key":"B126","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/mus.25969","article-title":"Autoimmune antibodies to collagen XIII in myasthenia gravis patients","volume":"57","author":"Tu","year":"2018","journal-title":"Muscle Nerve."},{"key":"B127","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2265.2004.02167.x","article-title":"Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy","volume":"62","author":"De Bellis","year":"2005","journal-title":"Clin Endocrinol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jneuroim.2016.04.004","article-title":"Screening for anti-titin antibodies in patients with various paraneoplastic neurological syndromes","volume":"296","author":"Berger","year":"2016","journal-title":"J Neuroimmunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain."},{"key":"B130","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B131","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve."},{"key":"B132","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis."},{"key":"B133","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","article-title":"Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis","volume":"262","author":"Iorio","year":"2015","journal-title":"J Neurol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol."},{"key":"B135","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1080\/14656566.2019.1682548","article-title":"Current pharmacotherapeutic options for myasthenia gravis","volume":"20","author":"Barnett","year":"2019","journal-title":"Expert Opin Pharmacother."},{"key":"B136","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3109\/08916930903518099","article-title":"Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis","volume":"43","author":"Lagoumintzis","year":"2010","journal-title":"Autoimmunity."},{"key":"B137","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1749-6632.2012.06788.x","article-title":"Antigen-specific apheresis of autoantibodies in myasthenia gravis","volume":"1275","author":"Lazaridis","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B138","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2014.12.001","article-title":"Specific adsorbents for myasthenia gravis autoantibodies using mutants of the muscle nicotinic acetylcholine receptor extracellular domains","volume":"278","author":"Lazaridis","year":"2015","journal-title":"J Neuroimmunol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jneuroim.2017.09.001","article-title":"Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis","volume":"312","author":"Lazaridis","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B140","doi-asserted-by":"publisher","first-page":"577136","DOI":"10.1016\/j.jneuroim.2019.577136","article-title":"Antigen-specific immunoadsorption of MuSK autoantibodies as a treatment of MuSK-induced experimental autoimmune myasthenia gravis","volume":"339","author":"Lazaridis","year":"2020","journal-title":"J Neuroimmunol."},{"key":"B141","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/ana.410360504","article-title":"Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis","volume":"36","author":"Okumura","year":"1994","journal-title":"Ann Neurol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0165-5728(94)00187-S","article-title":"Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor","volume":"58","author":"Ma","year":"1995","journal-title":"J Neuroimmunol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"8086","DOI":"10.1073\/pnas.96.14.8086","article-title":"Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit","volume":"96","author":"Barchan","year":"1999","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B144","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.1172\/JCI119857","article-title":"Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences","volume":"100","author":"Karachunski","year":"1997","journal-title":"J Clin Invest."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1172\/JCI7121","article-title":"Oral administration of an immunodominant T-cell epitope downregulates Th1\/Th2 cytokines and prevents experimental myasthenia gravis","volume":"104","author":"Baggi","year":"1999","journal-title":"J Clin Invest."},{"key":"B146","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.4049\/jimmunol.159.6.3016","article-title":"Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis","volume":"159","author":"Wu","year":"1997","journal-title":"J Immunol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.bcp.2015.07.011","article-title":"AChR-specific immunosuppressive therapy of myasthenia gravis","volume":"97","author":"Luo","year":"2015","journal-title":"Biochem Pharmacol."},{"key":"B148","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1196\/annals.1405.007","article-title":"Myasthenia gravis and the tops and bottoms of AChRs: antigenic structure of the MIR and specific immunosuppression of EAMG using AChR cytoplasmic domains","volume":"1132","author":"Lindstrom","year":"2008","journal-title":"Ann N Y Acad Sci."},{"key":"B149","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.4049\/jimmunol.1401392","article-title":"Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis","volume":"193","author":"Luo","year":"2014","journal-title":"J Immunol."},{"key":"B150","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1749-6632.1998.tb10910.x","article-title":"Molecular and antigenic structure of nicotinic acetylcholine receptors","volume":"841","author":"Lindstrom","year":"1998","journal-title":"Ann N Y Acad Sci."},{"key":"B151","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.molimm.2008.08.264","article-title":"Suppression of experimental myasthenia gravis by a B-cell epitope-free recombinant acetylcholine receptor","volume":"46","author":"Yi","year":"2008","journal-title":"Mol Immunol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/ana.21901","article-title":"Specific immunotherapy of experimental myasthenia gravis by a novel mechanism","volume":"67","author":"Luo","year":"2010","journal-title":"Ann Neurol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ijbiomac.2013.11.003","article-title":"Expression of human AChR extracellular domain mutants with improved characteristics","volume":"63","author":"Lazaridis","year":"2014","journal-title":"Int J Biol Macromol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3109\/08916930903541208","article-title":"Diagnostic use of autoantibodies in myasthenia gravis","volume":"43","author":"Leite","year":"2010","journal-title":"Autoimmunity."},{"key":"B155","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1749-6632.2012.06789.x","article-title":"Antibodies identified by cell-based assays in myasthenia gravis and associated diseases","volume":"1274","author":"Vincent","year":"2012","journal-title":"Ann N Y Acad Sci."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1001\/jamaneurol.2013.3553","article-title":"The road not taken: antigen-specific therapy and neuroinflammatory disease","volume":"70","author":"Steinman","year":"2013","journal-title":"JAMA Neurol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00212\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T17:36:28Z","timestamp":1695749788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.00212\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,14]]},"references-count":156,"alternative-id":["10.3389\/fimmu.2020.00212"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.00212","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,14]]},"article-number":"212"}}